Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Silence Therapeutics (NASDAQ:SLN) with a $55 price target.
August 16, 2024 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Silence Therapeutics with a $55 price target.
The reaffirmation of a Buy rating and a $55 price target by Chardan Capital is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100